Swiss drug company Roche has entered into a definite merger agreement to acquire Anadys Pharmaceuticals for $230 million.
The company said on Monday that it will buy Anadys, a developer of oral and small molecule therapeutics for the treatment of hepatitis C (HCV), for $3.70 a share in an all-cash transaction.
Go deeper with GlobalData
Setrobuvir (ANA598), Anadys’ most advanced drug candidate, is currently being evaluated by Anadys in a Phase II study in combination with Roche’s pegylated interferon (Pegasys) and ribavirin (Copegus).
Jean-Jacques Garaud, Global Head of Roche Pharma Research and Early Development, said: "This acquisition augments our already strong HCV portfolio. Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon."
Anadys is also developing ANA773, an oral, small-molecule inducer of innate immunity in Phase I trials that may prove useful for treating HCV and cancer.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
